ישראל - עברית - Ministry of Health

beit-erez havat milatin ltd - afoxolaner; milbemycin oxime - טבליות לעיסות - afoxolaner 75 mg; milbemycin oxime 15 mg

ישראל - עברית - Ministry of Health

beit-erez havat milatin ltd - afoxolaner; milbemycin oxime - טבליות לעיסות - afoxolaner 9.375 mg; milbemycin oxime 1.875 mg

ישראל - עברית - Ministry of Health

beit-erez havat milatin ltd - spiramycin - תמיסה להזרקה - spiramycin 600000 iu/ml

ישראל - עברית - Ministry of Health

beit-erez havat milatin ltd - metronidazole; spiramycin - טבליה - metronidazole 125 mg; spiramycin 750000 iu

ישראל - עברית - Ministry of Health

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - infliximab - אבקה להכנת תמיסה מרוכזת לעירוי - infliximab 100 mg/vial - infliximab

ישראל - עברית - Ministry of Health

novartis israel ltd - etanercept - תמיסה להזרקה - etanercept 25 mg / 0.5 ml - etanercept

ישראל - עברית - Ministry of Health

novartis israel ltd - etanercept - תמיסה להזרקה - etanercept 50 mg / 1 ml - etanercept

ישראל - עברית - Ministry of Health

kamada ltd, israel - teriparatide - תמיסה להזרקה - teriparatide 0.250 mg / 1 ml - teriparatide

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - simvastatin - קפליות - simvastatin 10 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvaxon is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures - reduce the risk of stroke and transient ischemic attacks (tia's). hyperlipidemia: simvaxon is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvaxon therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hype